Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670319 · ClinicalTrials.gov registry record · Phase 3
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,705
- Enrollment target
NCT00670319 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7,705 participants.
The verdict
NCT00670319, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,705 participants
- Enrollment target
Study Summary
To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
Interventions
- DRUG Placebo
- DRUG Raloxifene HCL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,705 participants |
| Start Date | 1994-11 |
| Est. Completion | 1999-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670319
The ClinicalTrials.gov registry entry for NCT00670319 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,705 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00670319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670319 about?
NCT00670319 is a clinical study titled "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis". To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
What is the current status of trial NCT00670319?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,705 participants. The study started on 1994-11. Estimated completion is 1999-09.
What interventions are being tested in trial NCT00670319?
The interventions under investigation include: Placebo (DRUG), Raloxifene HCL (DRUG).
Who is sponsoring clinical trial NCT00670319?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.